Chetan Bhardwaj, MD
Advanced Heart Failure and Transplant Cardiology · Peoria, ILNPI 1891950713
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,003 of the $4,935 with a category attached, or 60.8%. Abbott accounts for 67.4% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $2,001 and has fallen 93.6% since, to $127 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in IL, where the typical reported total is $11,038.
Across 55 payments — averaging $89.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Johnson & Johnson$276
- Abiomed$249
- Livanova USA, Inc.$178
- United Therapeutics Corporation$145
- Pfizer$142
- plus $621 from 12 others
Across 100 payments — averaging $3433.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$179K
- Janssen Research & Development, LLC$99K
- Vifor (international) Ltd.$42K
- United Therapeutics Corporation$24K
What the payments were for
- Travel & lodging$1,83837%
- Food & beverage$3,00361%
- Education$952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 29 | $3,325 |
| Johnson & Johnson | 3 | $276 |
| Abiomed | 2 | $249 |
| Livanova USA, Inc. | 4 | $178 |
| United Therapeutics Corporation | 2 | $145 |
| Pfizer | 2 | $142 |
| Impulse Dynamics (USA) Inc. | 1 | $126 |
| Actelion Pharmaceuticals US, Inc. | 1 | $95 |
| Cvrx, Inc. | 1 | $80 |
| Medtronic | 1 | $64 |
| Bayer | 1 | $63 |
| Merck | 1 | $48 |
| Endotronix, Inc. | 1 | $32 |
| Amgen | 1 | $27 |
| Eurofins Viracor, LLC | 1 | $27 |
| Edwards Lifesciences | 1 | $22 |
| AstraZeneca | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,487
- OPTIMIZER$251
- Impella$249
- XARELTO$233
- HeartMate 3 Left Ventricular Dev$142
- CARDIOMEMS$134
- LifeSPARC$126
- VYNDAQEL$125
- ORENITRAM$117
- TYVASO$117
- REMODULIN$117
How this compares
$4,935 in reported general payments places this provider in the 20th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
See all advanced heart failure and transplant cardiology providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 91 | $3,139,644 |
| EntrestoSacubitril/Valsartan | 1,058 | $1,248,497 |
| OpsumitMacitentan | 99 | $1,233,855 |
| JardianceEmpagliflozin | 914 | $975,891 |
| Tyvaso DpiTreprostinil | 29 | $704,446 |
| VyndaqelTafamidis Meglumine | 23 | $606,361 |
| AdempasRiociguat | 35 | $501,402 |
| WinrevairSotatercept-Csrk | 34 | $489,767 |
| CamzyosMavacamten | 32 | $264,442 |
| EliquisApixaban | 203 | $260,300 |
| FarxigaDapagliflozin Propanediol | 192 | $189,671 |
| VeltassaPatiromer Calcium Sorbitex | 56 | $60,081 |
| XareltoRivaroxaban | 52 | $52,796 |
| VerquvoVericiguat | 31 | $28,054 |
| Sildenafil Citrate | 98 | $23,284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $142 | $4,006,305317 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $95 | $1,233,85599 claims |
| MerckWinrevair, Verquvo | $48 | $517,82065 claims |
| BayerAdempas | $63 | $501,40235 claims |
| AstraZenecaFarxiga, Brilinta | $19 | $204,254215 claims |
| Johnson & JohnsonXarelto | $276 | $52,79652 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
Other advanced heart failure and transplant cardiology in Peoria
- Kavitha Kalvakuri-MeduruPeoria$7K
- Maria Rosa CostanzoNaperville$716K
- Jonathan RichChicago$327K
- Esther VorovichChicago$224K
- Jane WilcoxChicago$220K
- Ali ValikaElmhurst$218K
- Manreet KanwarChicago$162K
- Jonathan GrinsteinChicago$128K
- Muhyaldee DiaOak Lawn$125K
- Bow ChungChicago$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.